De Soto Choice Forza Tri Short 2020 - no FTS3 Pockets (no,thcasean.org,$97,-,De,2020,Forza,Pockets),Soto,Sports Outdoors , Sports Fitness , Exercise Fitness,Tri,/gendarme1140769.html,Short,FTS3 $97 De Soto Forza Tri Short - FTS3 (no Pockets) 2020 Sports Outdoors Sports Fitness Exercise Fitness De Soto Choice Forza Tri Short 2020 - no FTS3 Pockets $97 De Soto Forza Tri Short - FTS3 (no Pockets) 2020 Sports Outdoors Sports Fitness Exercise Fitness (no,thcasean.org,$97,-,De,2020,Forza,Pockets),Soto,Sports Outdoors , Sports Fitness , Exercise Fitness,Tri,/gendarme1140769.html,Short,FTS3
The Foza Tri Short offers compressive support where you need it most - in the quads and glutes; and less on the oh-so-comfortable Mobius Compression leg bands. Market feedback considers this short to be one of the best tri shorts for long and ultra distance racing. It is identical in all other aspects to the Forza 4-Pocket Tri Short model FTF3.
This amazing fabric lifts and supports muscles to dampen the vibration due to dynamic flexion and extension, as well as isometric flex during exercise. De Soto was the first company to produce compression garments in 1997. Since then we have offered Forza Products that have helped thousands of triathletes win as well as improve on their personal best. Research findings from extensive university studies show the Forza Compressor fabric used in our garments help to improve athletic performance by delaying the onset of fatigue by as much as 12%, and by giving an improved sense of body position. We assemble the garments of this fabric with proprietary articulated stitching techniques that maximize comfort and fit while minimizing constriction and drag. Consider each Forza garment as an “exterior ligament” for your body!
Mobius Comfort Compression
A Mobius Strip is a surface with only one side and one boundary. Mobius (aka Mobius Comfort Compression) is our new form-fitting, yet non-binding compressive fabric. When blending fibers the knit created makes repeated mobius loops so that the same surface is on both sides of the fabric. You will notice comfort and support without constriction, opacity without unnecessary weight, and durability from a very smooth surface on both sides. We use this fabric on the Mobius Tri Short and the Mobius Cycling Bibshort. We also use Mobius on the leg bands of all our shorts so there is no tight squeeze or binding on the legs.
Liftfoil3 is FINA approved hydrophobic and compressive fabric. It is hydrophobic because of a very tight Microweave, so tight it limits absorption of water and/or sweat. You should be weary of brands that use any types of teflon or waterproof coatings as these are just chemicals that are applied to finished fabrics. They do wear out after a number of uses. Those chemicals used by other companies have also yet to be proven by any reliable independent source to be perfectly safe against human skin for prolonged periods of time.
Liftfoil3 is knitted with coldBlack Technology — At speeds below 5 mph (8 kph) the best surface to flow though water is a smooth surface like Liftfoil. Liftfoil3 is designed to be worn very tight. When stretched on a moving body, Liftfoil3 becomes thinner, so it absorbs less water. Because it compresses against the skin, it reduces passive drag, and acts as a foil to lift the body at the water surface.
|Forza 4-Pocket Tri Short||Riviera Tri Short||Mobius 4-Pocket Tri Short||Carrera Tri Short||Carrera Low-Rise Tri Short|
|Pad||4mm Clasico Integrated Pad||7mm Clasico Integrated Pad||Seamless 1-piece, 4-way stretch minimalist fleece pad||Invisipad - a quick-drying, fleece tri-pad||Invisipad - a quick-drying, fleece tri-pad|
|Rise (waist height)||Mid-Rise||Low-Rise||Mid-Rise||Mid-Rise||Low-Rise|
|Inseam (size M)||8.5"||9.5"||8.5"||7"||7"|
|# of Pockets||None||2 Waterlid (hydrodynamic)||4 side leg|
|Legband style||3-inch Mobius Comfort Compression||3-inch Mobius Comfort Compression||3-inch Mobius Comfort Compression|
|Fabric Type||Forza Compressor - Compressive aka TIGHT||Forza Compressor - Compressive aka TIGHT||Mobius Comfort Compression for a supportive and comfortable compressive fit||Carrera - Fitted and non-abrasive||Carrera - Fitted and non-abrasive|
|Can be used for triathlon||Yes||Yes||Yes||Yes||Yes|
|Can be used for cycling||Yes||Yes||Yes||Yes||Yes|
Refer to our size chart image above for an accurate fit. Fit Note – Triathlon apparel is meant to fit next-to-skin. This is to eliminate unnecessary drag during the swim, bike and run and the potential to chafe. If you’re not comfortable with this type of fit and or are between sizes, we recommend sizing up. Garment will be the tightest the first time you put it on, it will relax slightly once worn or wet. Please keep in mind that a tight fit what eliminates the potential to chafe. If you're in doubt of your size, please ask us.
Inseam: Small 8", Medium: 8.5" , Large: 9" , XLarge: 9.5", XXLarge: 10"
Outseam: Small 14.25", Medium: 15.25" , Large: 16.25" , XLarge: 17.25", XXLarge: 18.25"
Front Rise: Small 9", Medium 9.5", Large 10", X-Large 10.5", XX-Large 11.6.
Back Rise: Small 10.5", Medium 11.5", Large 12", X-Large 12.5", XX-Large 13"
Zhu et al. report that intravenous immunoglobulin targets activated neutrophils in Kawasaki disease and multisystem inflammatory syndrome in children (MIS-C). The cover image is an artist’s rendering of immunoglobulin. Image credit: Kateryna Kon/Shutterstock.
S Indicates subscriber content
Chronic inflammation is a hallmark of atherosclerosis and results from an imbalance between pro-inflammatory and pro-resolving signaling. The human GPR32 receptor, together with the ALX/FPR2 receptor, transduces biological actions of several pro-resolving mediators that stimulate resolution of inflammation. However, since no murine homologs of the human GPR32 exist, comprehensive in vivo studies are lacking. Using human atherosclerotic lesions from carotid endarterectomies and creating a transgenic mouse model expressing human GPR32 on a Fpr2×apolipoprotein E double KO background (hGPR32myc×Fpr2-/-×Apoe-/-), we investigated the role of GPR32 in atherosclerosis and self-limiting acute inflammation. GPR32 mRNA was reduced in human atherosclerotic lesions and correlated with the immune cell markers ARG1, NOS2 and FOXP3. Atherosclerotic lesions, necrotic core and aortic inflammation were reduced in hGPR32mycTg×Fpr2-/-×Apoe-/- transgenic mice as compared to Fpr2-/-×Apoe-/- non-transgenic littermates. In a zymosan induced peritonitis model, the hGPR32mycTg×Fpr2-/-×Apoe-/- transgenic mice had reduced inflammation at 4h and enhanced pro-resolving macrophage responses at 24h compared to non-transgenic littermates. The GPR32 agonist aspirin-triggered resolvin D1 (AT-RvD1) regulated leukocyte responses, including enhancing macrophage phagocytosis and intracellular signaling in hGPR32mycTg×Fpr2-/-×Apoe-/- transgenic mice but not in the Fpr2-/-×Apoe-/- non-transgenic littermates. Altogether these results provide the first evidence that GPR32 regulates resolution of inflammation and is atheroprotective in vivo.
Hildur Arnardottir, Silke Thul, Sven-Christian Pawelzik, Glykeria Karadimou, Gonzalo Artiach, Alessandro L. Gallina, Victoria Mysdotter, Miguel Carracedo, Laura Tarnawski, April S. Caravaca, Roland Baumgartner, Daniel F.J. Ketelhuth, Peder S. Olofsson, Gabrielle Paulsson-Berne, Göran K. Hansson, Magnus Bäck
To delineate the in vivo role of different costimulatory signals in activating and expanding highly functional virus-specific cytotoxic CD8+ T cells, we designed synTacs, infusible biologics which recapitulate antigen-specific T-cell activation signals delivered by antigen-presenting cells. We constructed synTacs consisting of dimeric Fc-domain scaffolds linking CD28- or 4-1BB-specific ligands to HLA-A2 MHC molecules covalently-tethered to HIV- or CMV-derived peptides. Treatment of HIV-infected donor PBMCs with synTacs bearing HIV- or CMV-derived peptides induced vigorous and selective ex vivo expansion of highly functional HIV- and/or CMV-specific CD8+ T cells, respectively, with potent anti-viral activities. Intravenous injection of HIV or CMV-specific synTacs into immunodeficient mice intrasplenically engrafted with donor PBMCs markedly and selectively expanded HIV-specific (32-fold) or CMV-specific (46-fold) human CD8+ T cells populating their spleens, respectively. Notably, these expanded HIV or CMV-specific CD8+ T cells directed potent in vivo suppression of HIV or CMV infections, respectively, in the humanized mice providing strong rationale for consideration of synTac-based approaches as a therapeutic strategy to cure HIV and treat CMV and other viral infections. The synTac platform flexibility supports facile delineation of in vivo effects of different costimulatory signals on patient-derived virus-specific CD8+ T cells, enabling optimization of individualized therapies, including HIV cure strategies.
Mengyan Li, Scott J. Garforth, Kaitlyn E. O’Connor, Hang Su, Danica M. Lee, Alev Celikgil, Rodolfo J. Chaparro, Ronald D. Seidel, R. Brad Jones, Ravit Arav-Boger, Steven C. Almo, Harris Goldstein
Genome-wide association studies (GWAS) involve testing genetic variants across the genomes of many individuals to identify genotype-phenotype associations. GWAS have enabled the identification of numerous genomic biomarkers in various complex human diseases including infectious ones. However, few of these studies are relevant for clinical practice or at the bedside. In this issue of the JCI, Nakanishi et al. characterized the clinical implications of a major genetic risk factor for COVID-19 severity and its age-dependent effect, using individual-level data in a large international multi-center consortium. This study indicates that a common COVID-19 genetic risk factor (rs10490770) associates with increased risks of morbidity and mortality, suggesting potential implications for future clinical risk management. How can the genomic biomarkers identified by GWAS be associated with the clinical outcomes of an infectious disease? In this commentary, we evaluate the advantages and limitations of this approach.
Vito Luigi Colona, Michela Bianocolella, Antonio Novelli, Giuseppe Novelli
Contrasting with the predicted anorexigenic effect of increasing brain serotonin signaling, long-term use of selective serotonin reuptake inhibitors (SSRIs) antidepressants correlates with body weight gain. This adverse outcome increases the risk of transitioning to obesity and interferes with treatment compliance. Here we show that orally administered fluoxetine (Flx), a widely prescribed SSRI, increased body weight by enhancing food intake in healthy mice at two different time points and through two distinct mechanisms. Within hours, Flx decreased the activity of a subset of brainstem serotonergic neurons by triggering autoinhibitory signaling through the Htr1a receptor. Upon longer treatment Flx blunted Htr2c expression/signaling, decreased the phosphorylation of Creb and Stat3 and dampened the production of POMC/α-MSH in hypothalamic neurons, thereby increasing food intake. Accordingly, exogenous stimulation of the melanocortin 4 receptor (MC4R) by co-treating mice with Flx and lipocalin-2, an anorexigenic hormone signaling through this receptor, normalized feeding and body weight. Flx and other SSRIs also inhibit CREB/STAT3 phosphorylation in a human neuronal cell line suggesting that these non-canonical effects could also occur in long-term users of SSRIs. By defining the molecular basis of the long-term SSRIs-associated weight gain this study proposes a therapeutic strategy to counter it.
Maria Jose Ortuno, Marc Schneeberger, Anoj Ilanges, François Marchildon, Kyle Pellegrino, Jeffrey M. Friedman, Patricia Ducy
BACKGROUND. A long-held dream of scientists is to transfer information directly to the visual cortex of blind individuals, thereby restoring a rudimentary form of sight. However, no clinically available cortical visual prosthesis yet exists. METHODS.We implanted an intracortical microelectrode array consisting of 96 electrodes in the visual cortex of a 57-year-old person with complete blindness for a six- month period. We measured thresholds and the characteristics of the visual percepts elicited by intracortical microstimulation. RESULTS. Implantation and subsequent explantation of intracortical microelectrodes were carried out without complications. The mean stimulation threshold for single electrodes was 66.8 ± 36.5 μA. We consistently obtained high-quality recordings from visually deprived neurons and the stimulation parameters remained stable over time. Simultaneous stimulation via multiple electrodes were associated with a significant reduction in thresholds (p<0.001, ANOVA test) and evoked discriminable phosphene percepts, allowing the blind participant to identify some letters and recognize object boundaries. Furthermore, we observed a learning process that helped the subject to recognize complex patterns over time. CONCLUSIONS. Our results demonstrate the safety and efficacy of chronic intracortical microstimulation via a large number of electrodes in human visual cortex, showing its high potential for restoring functional vision in the blind. TRIAL REGISTRATION. ClinicalTrials.gov identifier NCT02983370. FUNDING. Funding was provided by grant RTI2018-098969-B-100 from the Spanish Ministerio de Ciencia Innovación y Universidades, by grant PROMETEO/2019/119 from the Generalitat Valenciana (Spain), by the Bidons Egara Research Chair of the University Miguel Hernández (Spain) and by the John Moran Eye Center of the University of Utah (US).
Eduardo Fernández, Arantxa Alfaro, Cristina Soto-Sánchez, Pablo González-López, Antonio M. Lozano Ortega, Sebastian Peña, María Dolores Grima, Alfonso Rodil, Bernardeta Gómez, Xing Chen, Pieter R. Roelfsema, John D. Rolston, Tyler S. Davis, Richard A. Normann
JCI This Month is a digest of the research, reviews, and other features published each month.
Animals, plants, and bacteria all display behavioral patterns that coincide with Earth’s light and dark cycles. These oscillating behaviors are the manifestation of the molecular circadian clock, a highly conserved network that maintains a near 24-hour rhythm even in the absence of light. In mammals, light signals are transmitted via the superchiasmatic nucleus (SCN) in the hypothalamus to synchronize peripheral clocks and coordinate physiological functions with the organism’s active period. This collection of reviews, curated by Amita Sehgal, considers the critical role of the circadian system in human health. Technology, work, and social obligations can disrupt optimal sleep and wake schedules, leaving humans vulnerable to diseases affecting the heart, brain, metabolism, and more. Sleep disorders as well as normal variations in human chronotype may exacerbate circadian disruptions, with profound consequences. These reviews emphasize that ongoing efforts to understand the complexities of human circadian rhythm will be essential for developing chronotherapies and other circadian-based interventions.